3rd Circ. Affirms Takeda's Nix Of Prevacid Antitrust Claims
The Third Circuit affirmed a lower court decision nixing allegations from Zydus Pharmaceuticals Inc. that Takeda Pharmaceutical Co. used sham patent litigation to delay generic competition for its heartburn medication Prevacid,...To view the full article, register now.
Already a subscriber? Click here to view full article